Chronic Lower Back Pain Global Market Report 2024

The chronic lower back pain market size has grown strongly in recent years. It will grow from $7.3 billion in 2023 to $7.67 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historical period regarding chronic low back pain (CLBP) can be attributed to several key factors. These include the prevalence of sedentary lifestyles leading to increased susceptibility to back issues, occupational risks and manual labor often causing strains and injuries, advancements in medical diagnosis aiding in better identification of CLBP, the evolution of pain management strategies contributing to improved treatment options, and the insights gained from epidemiological studies that enhanced our understanding of this condition. These factors collectively contributed to the growth and understanding of chronic low back pain during that period.

The chronic lower back pain market size is expected to see steady growth in the next few years. It will grow to $9.27 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. Anticipated growth in the forthcoming period regarding chronic low back pain (CLBP) can be attributed to several factors. These include the increased adoption and emphasis on non-pharmacological interventions for managing CLBP, the implementation of preventive healthcare initiatives aimed at addressing back-related issues before they escalate, a greater focus on holistic treatments encompassing various aspects of well-being, ongoing advancements in regenerative medicine offering promising solutions, and the demographic trend of an aging population more prone to such conditions. Key trends expected in the forecast period include a heightened emphasis on non-pharmacological interventions as a primary approach for managing CLBP, a notable shift in pain management strategies to incorporate a wider range of treatments, increased healthcare awareness and education regarding CLBP prevention and management, the utilization of telemedicine and remote monitoring for efficient patient care, and the integration of regenerative medicine approaches into the treatment spectrum for chronic low back pain.

The chronic lower back pain market is expected to witness growth driven by an increase in the frequency of nerve instances. In this context, nerve instances refer to specific occurrences where individuals display bravery, courage, or resilience in challenging situations. Continuous exposure to stress and pain can lead to central sensitization, a phenomenon where the nervous system becomes hypersensitive, intensifying the perception of pain even in the absence of actual injury. As reported by Nature in July 2023, the prevalence of peripheral neuropathy, associated with nerve damage, is 28.4% in adults aged 40 or older with diabetes and 11.8% in those without diabetes. The rising frequency of nerve instances contributes to the growth of the chronic lower back pain market.

The growth of the chronic lower back pain market is further propelled by the increasing geriatric population. The term 'geriatric population' refers to individuals aged 65 and above. Among this demographic, age-related neurodegenerative and musculoskeletal conditions such as arthritis and osteoarthritis progress rapidly, leading to weakness and painful complaints resulting in chronic back pain and reduced physical activities. According to data released by the World Trade Organization in October 2022, the proportion of the global population aged 60 and above increased from 1 billion to 1.4 billion from 2020 to 2021. By 2050, the world's population of adults aged 60 and above is projected to double to 2.1 billion, with the number of people aged 80 or more predicted to triple between 2020 and 2050, reaching 426 million. The growth in the geriatric population is a significant driver for the chronic lower back pain market.

Technological advancements emerge as a key trend gaining popularity in the chronic lower back pain market. Major companies within this market are actively involved in developing new and improved advanced technologies for the treatment and prevention of lower back pain to maintain their competitive positions. In December 2022, Abbott Laboratories, a US-based medical devices and healthcare company, introduced the Eterna spinal cord stimulation (SCS) device. Recognized as the world's smallest implantable, rechargeable spinal cord stimulator for treating chronic pain, the Eterna SCS device, featuring Abbott's low-dose BurstDR stimulation technology, has received approval from the US Food and Drug Administration (FDA). This technological innovation demonstrates the commitment of major companies to advancing the treatment options for chronic lower back pain.

Major companies in the chronic lower back pain market are actively engaged in the development of products incorporating advanced technologies, such as BurstDR SCS technology, to introduce innovative options for patients. BurstDR SCS technology is a proprietary therapy within the spinal cord stimulation (SCS) category, employing mild electrical pulses to modify pain signals during their transmission from the spinal cord to the brain. An illustration of this technological advancement is evident in the case of Abbott Laboratories, a prominent US-based medical device company. In May 2023, Abbott Laboratories received approval from the US Food and Drug Administration (FDA) for its Spinal Cord Stimulation (SCS) devices, which include the Proclaim SCS Family and Eterna SCS System specifically designed for treating chronic back pain. Abbott's SCS devices utilize the proprietary BurstDR stimulation waveform, offering a superior therapy that closely replicates the pathway of pain signals to the brain, effectively addressing the emotional aspects associated with pain. This stands in contrast to traditional tonic stimulation methods.

In September 2022, The National Science Foundation (NSF), an independent US-based agency focusing on fundamental research and education in science, collaborated with a multidisciplinary team led by researchers at the University of California, San Diego. This collaboration involved a substantial investment of $1.2 million and aimed to study and advance the treatment of chronic low back pain. The research initiative focuses on implementing remote monitoring of patients' posture and mobility throughout the day, facilitating individualized physical therapy treatments to optimize health outcomes. This collaborative effort underscores the commitment to leveraging technology and interdisciplinary research to enhance the understanding and management of chronic lower back pain.

Major companies operating in the chronic lower back pain market report are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy's Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc..

North America was the largest region in the chronic lower back pain market in 2023. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic lower back pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of chronic lower back pain encompass discogenic pain, lumbar spinal stenosis, sacroiliac pain, facet-joint pain, radicular pain, muscular pain, and other variants. Discogenic pain specifically originates from damage to spinal discs, commonly associated with conditions such as degenerative disc disease, which occurs naturally as part of the aging process. Diagnosis typically involves a comprehensive clinical history, physical examination, imaging assessments, and pain evaluation. Treatment is administered across various healthcare facilities, including hospitals, orthopedic clinics, ambulatory surgery centers, among others.

The chronic lower back pain market research report is one of a series of new reports that provides chronic lower back pain market statistics, including chronic lower back pain industry global market size, regional shares, competitors with a chronic lower back pain market share, detailed chronic lower back pain market segments, market trends and opportunities, and any further data you may need to thrive in the chronic lower back pain industry. This chronic lower back pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.